4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

Author:

Long Georgina V.1,Schachter Jacob2,Ribas Antoni3,Arance Ana M.4,Grob Jean-Jacques5,Mortier Laurent6,Daud Adil7,Carlino Matteo S.8,McNeil Catriona M.9,Lotem Michal10,Larkin James M. G.11,Lorigan Paul12,Neyns Bart13,Blank Christian U.14,Petrella Teresa M.15,Hamid Omid16,Anderson James17,Krepler Clemens18,Ibrahim Nageatte19,Robert Caroline20

Affiliation:

1. Melanoma Institute Australia, The University of Sydney, Mater Hospital, and Royal North Shore Hospital, Sydney, Australia;

2. Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel;

3. University of California, Los Angeles, Los Angeles, CA;

4. Hospital Clínic de Barcelona, Barcelona, Spain;

5. Aix-Marseille University, Hopital de la Timone, Marseille, France;

6. Université Lille, Centre Hospitalier Régional Universitaire de Lille, Lille, France;

7. University of California, San Francisco, San Francisco, CA;

8. Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, Australia;

9. Chris O'Brien Lifehouse, Camperdown, Australia;

10. Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;

11. The Royal Marsden Hospital, London, United Kingdom;

12. University of Manchester and the Christie NHS Foundation Trust, Manchester, United Kingdom;

13. Universitair Ziekenhuis Brussel, Brussels, Belgium;

14. Netherlands Cancer Institute, Amsterdam, Netherlands;

15. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada;

16. The Angeles Clinic and Research Institute, Los Angeles, CA;

17. Merck & Co., Inc., Kenilworth, NJ;

18. Merck & Co., Inc., Kenilworth, NJ, US;

19. Merck & Co, Inc., Kenilworth, NJ;

20. Gustave Roussy Institute, Paris, France;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3